Form 8-K - Current report:
SEC Accession No. 0001193125-24-247628
Filing Date
2024-10-30
Accepted
2024-10-30 16:45:53
Documents
18
Period of Report
2024-10-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d890797d8k.htm   iXBRL 8-K 27199
2 EX-10.1 d890797dex101.htm EX-10.1 9339
3 EX-99.1 d890797dex991.htm EX-99.1 13496
7 GRAPHIC g890797g1028031449905.jpg GRAPHIC 2307
8 GRAPHIC g890797g1028042044328.jpg GRAPHIC 2613
9 GRAPHIC g890797g65c10.jpg GRAPHIC 7509
  Complete submission text file 0001193125-24-247628.txt   201289

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA biib-20241028.xsd EX-101.SCH 2861
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE biib-20241028_lab.xml EX-101.LAB 17237
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE biib-20241028_pre.xml EX-101.PRE 10820
20 EXTRACTED XBRL INSTANCE DOCUMENT d890797d8k_htm.xml XML 3477
Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142
Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
BIOGEN INC. (Filer) CIK: 0000875045 (see all company filings)

EIN.: 330112644 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19311 | Film No.: 241411006
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)